Rituximab biosimilar (AryoGen Biopharma)

利妥昔单抗生物类似药 (AryoGen Biopharma)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (AryoGen Biopharma)
Drug Alias Name利妥昔单抗生物仿制药 (AryoGen Biopharma)Zytux
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMicroscopic PolyangiitisGranulomatosis with PolyangiitisArthritis, Rheumatoid +[5] 
Global Approved IndicationsMicroscopic PolyangiitisGranulomatosis with PolyangiitisArthritis, Rheumatoid +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2014/01/01
Country/TerritoryIran
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAryogen Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesAryogen Biopharma
Inactive CompaniesN/A
Active IndicationsMicroscopic PolyangiitisGranulomatosis with PolyangiitisArthritis, Rheumatoid +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC02
Related LinksN/A